MiR-223 Exclusively Impairs In Vitro Tumor Growth through IGF1R Modulation in Rhabdomyosarcoma of Adolescents and Young Adults.
Michela CasanovaFrancesca PontisPatrizia GhidottiIlaria PetraroiaLara Veronica VenturiniLuca BergamaschiStefano ChiaravalliLoris De CeccoMaura MassiminoGabriella SozziAndrea C FerrariOrazio FortunatoPatrizia GaspariniPublished in: International journal of molecular sciences (2022)
Adolescents and young adults (AYA) with rhabdomyosarcoma (RMS) form a subgroup of patients whose optimal clinical management and best possible access to care remain a challenge and whose survival rates lag behind that of children diagnosed with histologically similar tumors. A better understanding of tumor biology that differentiates children (PEDS-) from AYA-RMS could provide critical information and drive new initiatives to improve their final outcome. We investigated the functional role of miRNAs implicated in AYA-RMS development, as they have the potential to lead to discovery of new targets pathways for a more tailored treatment in these age groups of young RMS patients. MiR-223 and miR-486 were observed de-regulated in nine RMS tissues compared to their normal counterparts, yet only miR-223 replacement impaired proliferation and aggressiveness of AYA-RMS cell lines, while inducing apoptosis and determining cell cycle arrest. Interestingly, IGF1R resulted in the direct target of miR-223 in AYA-RMS cells, as demonstrated by IGF1R silencing. Our results highlight an exclusive functional role of miR-223 in AYA-RMS development and aggressiveness.
Keyphrases
- cell proliferation
- cell cycle arrest
- long non coding rna
- pi k akt
- long noncoding rna
- end stage renal disease
- cell death
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- young adults
- signaling pathway
- prognostic factors
- oxidative stress
- small molecule
- binding protein
- gene expression
- palliative care
- clinical trial
- chronic pain
- patient reported outcomes
- endoplasmic reticulum stress
- high throughput
- patient reported
- pain management
- growth hormone